Ribonucleotide Reductase Large Subunit (RRM1) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer
Open Access
- 14 June 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (12), 3452-3461
- https://doi.org/10.1158/1078-0432.ccr-11-2692
Abstract
Purpose: Mitotane is the most broadly used systemic therapy for adrenocortical carcinoma (ACC), but its mechanism of action and possible predictors of treatment response are currently poorly defined. Our aim was to evaluate the gene expression of ribonucleotide reductase large subunit 1 (RRM1) and excision repair cross-complementation group 1 (ERCC1) in ACC as potential biomarkers for clinical outcome and response to mitotane. Experimental Design: Forty-five and 47 tissue samples from two cohorts (Orbassano, Italy; Wuerzburg, Germany) of completely resected ACC were centrally analyzed using real-time PCR for RRM1 and ERCC1 expression. Fifty-four patients received surgery alone and 38 received adjuvant mitotane after surgery. Clinical and pathologic features were highly comparable in the two series. H295R and SW-13 ACC cell lines were also used for pharmacologic tests. Results: ERCC1 gene expression was not associated to clinical outcome. In contrast, high RRM1 gene expression was associated to shorter disease-free survival (DFS) and overall survival at both univariate and multivariate analysis. In patients with low RRM1 gene expression, adjuvant mitotane was associated with improved DFS, whereas this effect was lost in cases with high RMM1 expression. In vitro mitotane induced strong up regulation of RRM1 transcription (up to 25-fold increase) in mitotane-insensitive SW-13 but not in mitotane-sensitive H295R cells. Furthermore, RRM1 silencing in SW-13 cells induced sensitivity to mitotane. Conclusion: Our in vitro and in vivo data indicate that RRM1 gene expression is functionally associated to mitotane sensitivity and support a possible role of RRM1 determination as a novel molecular biomarker predicting response to adjuvant mitotane in ACC. Clin Cancer Res; 18(12); 3452–61. ©2012 AACR.Keywords
Other Versions
This publication has 41 references indexed in Scilit:
- Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinomaEndocrine-Related Cancer, 2010
- Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulationInternational Journal of Oncology, 2010
- The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotaneEndocrine-Related Cancer, 2010
- Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical CarcinomaJournal of Clinical Oncology, 2009
- Adjuvant Mitotane Treatment for Adrenocortical CarcinomaThe New England Journal of Medicine, 2007
- Adjuvant Mitotane Therapy of Adrenal Cancer — Use and ControversyThe New England Journal of Medicine, 2007
- Prognostic Parameters of Metastatic Adrenocortical CarcinomaJournal of Clinical Endocrinology & Metabolism, 2007
- Adrenocortical Carcinoma: Clinical UpdateJournal of Clinical Endocrinology & Metabolism, 2006
- Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: diagnostic and prognostic significance in a series of 50 adrenocortical carcinomasLaboratory Investigation, 2006
- In vitro macromolecular binding of 2-(2-chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane (o,p′-DDD) in the mouse lung and liverChemico-Biological Interactions, 1989